Imexpharm (IMP.VN) Stock Price

Imexpharm Price

CLOSED
40,300.00VND+1,300.00 (+3.28 %)
Market closed

Revenue has compounded at 8.4% per year over the past 19 years to 2.44 T VND. Earnings per share have grown at 0.6% per year over the last 19 years. Imexpharm's net margin stands at 12.5%, down from 13.7% several years earlier. Imexpharm currently offers a dividend yield of about 1.24%. The payout ratio is around 25% of earnings. Analysts set a median price target of 54,570.00 VND, implying 35.4% above the current price. Of 6 analysts, 5 rate the stock a buy — an overall Buy consensus. The stock trades about 3% above its 52-week low.

Imexpharm stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Imexpharm over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Imexpharm stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Imexpharm's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Imexpharm Stock Price History
DateImexpharm Price
7/16/202640,300.00 VND
7/15/202639,000.00 VND
7/14/202639,000.00 VND
7/13/202639,600.00 VND
7/10/202641,200.00 VND
7/9/202641,500.00 VND
7/8/202641,700.00 VND
7/7/202641,800.00 VND
7/6/202642,900.00 VND
7/3/202642,950.00 VND
7/2/202642,700.00 VND
7/1/202641,800.00 VND
6/30/202641,200.00 VND
6/29/202641,350.00 VND
6/26/202642,050.00 VND
6/25/202642,900.00 VND
6/24/202643,500.00 VND
6/23/202643,700.00 VND
6/22/202644,200.00 VND
6/19/202645,500.00 VND
6/18/202645,600.00 VND
6/17/202645,900.00 VND
6/16/202646,100.00 VND
6/15/202646,150.00 VND
6/12/202646,150.00 VND
6/11/202646,150.00 VND
6/10/202646,150.00 VND
6/9/202646,000.00 VND
6/8/202645,800.00 VND
6/5/202645,800.00 VND
6/4/202646,000.00 VND
6/3/202645,300.00 VND
6/2/202645,900.00 VND
6/1/202646,100.00 VND
5/29/202646,100.00 VND
5/28/202646,100.00 VND
5/27/202646,500.00 VND
5/26/202646,600.00 VND
5/25/202646,300.00 VND
5/22/202646,650.00 VND
5/21/202646,900.00 VND
5/20/202646,800.00 VND
5/19/202647,000.00 VND
5/18/202646,250.00 VND
5/15/202647,050.00 VND
5/14/202647,750.00 VND
5/13/202647,700.00 VND
5/12/202646,850.00 VND
5/11/202646,850.00 VND
5/8/202648,100.00 VND
5/7/202647,600.00 VND
5/6/202649,200.00 VND
5/5/202649,900.00 VND
5/4/202649,900.00 VND
5/1/202650,800.00 VND
4/30/202650,800.00 VND
4/29/202650,800.00 VND
4/28/202647,500.00 VND
4/27/202648,350.00 VND
4/24/202648,350.00 VND
4/23/202649,800.00 VND
4/22/202651,300.00 VND
4/21/202655,100.00 VND
4/20/202656,000.00 VND
4/17/202656,200.00 VND
4/16/202655,900.00 VND
4/15/202655,900.00 VND
4/14/202656,000.00 VND
4/13/202655,900.00 VND
4/10/202655,500.00 VND
4/9/202655,600.00 VND
4/8/202655,600.00 VND
4/7/202655,500.00 VND
4/6/202655,700.00 VND
4/3/202655,700.00 VND
4/2/202655,600.00 VND
4/1/202655,700.00 VND
3/31/202654,700.00 VND
3/30/202655,000.00 VND
3/27/202654,800.00 VND
3/26/202654,500.00 VND
3/25/202655,200.00 VND
3/24/202655,000.00 VND
3/23/202654,400.00 VND
3/20/202654,500.00 VND
3/19/202655,000.00 VND
3/18/202655,100.00 VND
3/17/202656,100.00 VND
3/16/202655,600.00 VND
3/13/202655,000.00 VND
3/12/202656,100.00 VND
3/11/202656,700.00 VND
3/10/202656,400.00 VND
3/9/202653,700.00 VND
3/6/202653,900.00 VND
3/5/202654,300.00 VND
3/4/202654,200.00 VND
3/3/202654,000.00 VND
3/2/202654,000.00 VND
2/27/202654,000.00 VND
2/26/202653,900.00 VND
2/25/202653,900.00 VND
2/24/202653,900.00 VND
2/23/202653,700.00 VND
2/13/202653,400.00 VND
2/12/202653,800.00 VND
2/11/202653,900.00 VND
2/10/202653,800.00 VND
2/9/202654,000.00 VND
2/6/202654,100.00 VND
2/5/202654,200.00 VND
2/4/202654,100.00 VND
2/3/202654,100.00 VND
2/2/202654,000.00 VND
1/30/202654,200.00 VND
1/29/202653,800.00 VND
1/28/202653,800.00 VND
1/27/202653,700.00 VND
1/26/202653,900.00 VND
1/23/202653,700.00 VND
1/22/202653,600.00 VND
1/21/202653,600.00 VND
1/20/202653,600.00 VND
1/19/202654,500.00 VND
1/16/202654,200.00 VND
1/15/202653,700.00 VND
1/14/202653,200.00 VND
1/13/202653,100.00 VND
1/12/202652,300.00 VND
1/9/202652,500.00 VND
1/8/202652,500.00 VND
1/7/202652,500.00 VND
1/6/202651,800.00 VND
1/5/202652,100.00 VND
12/31/202552,500.00 VND
12/30/202551,700.00 VND
12/29/202550,700.00 VND
12/26/202550,500.00 VND
12/25/202550,600.00 VND
12/24/202550,100.00 VND
12/23/202550,200.00 VND
12/22/202550,300.00 VND
12/19/202549,900.00 VND
12/18/202549,500.00 VND
12/17/202549,600.00 VND
12/16/202549,000.00 VND
12/15/202548,550.00 VND
12/12/202548,600.00 VND
12/11/202549,000.00 VND
12/10/202548,700.00 VND
12/9/202549,100.00 VND
12/8/202549,200.00 VND
12/5/202550,200.00 VND
12/4/202550,100.00 VND
12/3/202550,100.00 VND
12/2/202550,400.00 VND
12/1/202549,300.00 VND
11/28/202547,600.00 VND
11/27/202547,500.00 VND
11/26/202547,400.00 VND
11/25/202547,000.00 VND
11/24/202547,300.00 VND
11/21/202546,100.00 VND
11/20/202547,250.00 VND
11/19/202547,250.00 VND
11/18/202548,400.00 VND
11/17/202548,300.00 VND
11/14/202548,700.00 VND
11/13/202548,000.00 VND
11/12/202549,450.00 VND
11/11/202549,250.00 VND
11/10/202549,300.00 VND
11/7/202548,650.00 VND
11/6/202549,450.00 VND
11/5/202548,850.00 VND
11/4/202548,950.00 VND
11/3/202549,500.00 VND
10/31/202550,100.00 VND
10/30/202548,550.00 VND
10/29/202548,800.00 VND
10/28/202548,950.00 VND
10/27/202548,950.00 VND
10/24/202549,000.00 VND
10/23/202549,500.00 VND
10/22/202549,750.00 VND
10/21/202549,500.00 VND
10/20/202548,000.00 VND
10/17/202550,600.00 VND
10/16/202550,600.00 VND
10/15/202551,000.00 VND
10/14/202550,700.00 VND
10/13/202551,000.00 VND
10/10/202551,900.00 VND
10/9/202552,000.00 VND
10/8/202552,100.00 VND
10/7/202552,400.00 VND
10/6/202552,400.00 VND
10/3/202552,500.00 VND
10/2/202552,500.00 VND
10/1/202553,000.00 VND
9/30/202552,900.00 VND
9/29/202552,700.00 VND
9/26/202553,000.00 VND
9/25/202553,200.00 VND
9/24/202553,100.00 VND
9/23/202553,300.00 VND
9/22/202553,200.00 VND
9/19/202553,400.00 VND
9/18/202553,100.00 VND
9/17/202554,000.00 VND
9/16/202553,300.00 VND
9/15/202554,600.00 VND
9/12/202554,500.00 VND
9/11/202554,400.00 VND
9/10/202554,500.00 VND
9/9/202554,900.00 VND
9/8/202555,400.00 VND
9/5/202553,800.00 VND
9/4/202554,700.00 VND
9/3/202554,700.00 VND
8/29/202553,800.00 VND
8/28/202552,300.00 VND
8/27/202552,500.00 VND
8/26/202552,600.00 VND
8/25/202552,700.00 VND
8/22/202553,200.00 VND
8/21/202554,000.00 VND
8/20/202552,800.00 VND
8/19/202554,300.00 VND
8/18/202554,900.00 VND
8/15/202555,000.00 VND
8/14/202554,000.00 VND
8/13/202554,600.00 VND
8/12/202553,000.00 VND
8/11/202553,100.00 VND
8/8/202553,900.00 VND
8/7/202552,400.00 VND
8/6/202552,600.00 VND
8/5/202553,800.00 VND
8/4/202554,300.00 VND
8/1/202552,700.00 VND
7/31/202552,000.00 VND
7/30/202550,500.00 VND
7/29/202551,000.00 VND
7/28/202551,900.00 VND
7/25/202551,900.00 VND
7/24/202552,000.00 VND
7/23/202552,000.00 VND
7/22/202552,200.00 VND
7/21/202552,000.00 VND
Access this data via the Eulerpool API
Get Free API Key

Imexpharm Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
1.37 T VND
249.48 B VND
179.66 B VND
Jan 1, 2021
1.27 T VND
220.28 B VND
173.37 B VND
Jan 1, 2022
1.64 T VND
276.28 B VND
183.84 B VND
Jan 1, 2023
1.99 T VND
357.96 B VND
277.78 B VND
Jan 1, 2024
2.21 T VND
394.60 B VND
297.54 B VND
Jan 1, 2025
2.44 T VND
462.44 B VND
304.39 B VND
Jan 1, 2026 (e)
2.91 T VND
571.32 B VND
389.24 B VND
Jan 1, 2027 (e)
3.28 T VND
649.43 B VND
451.25 B VND

Imexpharm Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 19, 2026, 3:17 AM
 
REVENUET VND
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMET VND
EBITB VND
EBIT MARGIN%
NET INCOMEB VND
NET INCOME GROWTH%
DIV.VND
DIV. GROWTH%
SHARESM
201220132014201520162017201820192020202120222023202420252026e2027e
0.820.840.900.961.011.171.181.401.371.271.641.992.212.442.913.28
5.382.846.637.494.7715.351.6618.37-2.36-7.5129.7721.3110.5910.7019.0112.91
46.1546.3446.6939.7440.0937.4839.6437.6439.9538.5342.4340.6538.8041.0341.0341.03
0.380.390.420.380.410.440.470.530.550.490.700.810.861.001.191.35
98.1988.62101.69106.34119.36129.10158.39189.23249.48220.28276.28357.96394.60462.44571.32649.43
12.0010.5311.3411.0311.8111.0813.3713.4918.2217.3916.8117.9517.8918.9419.6719.80
77.6160.6285.7878.9788.01103.28122.04142.90179.66173.37183.84277.78297.54304.39389.24451.25
0.01-21.8941.49-7.9311.4417.3518.1717.0925.72-3.506.0451.097.112.3027.8715.93
3,290.912,000.001,500.001,800.002,000.001,227.27–2,000.00769.231,500.001,500.00952.38909.09500.00514.62529.67
49.59-39.23-25.0020.0011.11-38.64––-61.5495.00–-36.51-4.55-45.002.922.92
31.0033.0033.2749.9249.0962.1764.2264.2468.02154.01154.01154.01154.01154.01154.01154.01
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Imexpharm generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Imexpharm retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Imexpharm's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Imexpharm has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Imexpharm's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Imexpharm stock margins

The Imexpharm margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Imexpharm. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Imexpharm.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
39.95 %
18.22 %
13.12 %
Jan 1, 2021
38.53 %
17.39 %
13.69 %
Jan 1, 2022
42.43 %
16.81 %
11.18 %
Jan 1, 2023
40.65 %
17.95 %
13.93 %
Jan 1, 2024
38.80 %
17.89 %
13.49 %
Jan 1, 2025
41.03 %
18.94 %
12.47 %
Jan 1, 2026 (e)
41.03 %
19.67 %
13.40 %
Jan 1, 2027 (e)
41.03 %
19.80 %
13.76 %

Imexpharm Stock Revenue, EBIT, Earnings per Share

The Imexpharm earnings per share therefore indicates how much revenue Imexpharm has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
20,131.92 VND
3,667.62 VND
2,641.16 VND
Jan 1, 2021
8,224.04 VND
1,430.25 VND
1,125.68 VND
Jan 1, 2022
10,672.70 VND
1,793.91 VND
1,193.71 VND
Jan 1, 2023
12,947.53 VND
2,324.28 VND
1,803.65 VND
Jan 1, 2024
14,318.12 VND
2,562.16 VND
1,931.94 VND
Jan 1, 2025
15,850.28 VND
3,002.65 VND
1,976.44 VND
Jan 1, 2026 (e)
18,863.16 VND
3,709.67 VND
2,527.36 VND
Jan 1, 2027 (e)
21,298.39 VND
4,216.83 VND
2,930.01 VND

Imexpharm business model & stock analysis

Imexpharm Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Imexpharm historical P/E ratio, EBIT multiple, and P/S ratio

Imexpharm annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Imexpharm shares outstanding

The number of shares of Imexpharm was 154.01 M in 2025. This indicates how many shares Imexpharm is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
68.02 M Stocks
Jan 1, 2021
154.01 M Stocks
Jan 1, 2022
154.01 M Stocks
Jan 1, 2023
154.01 M Stocks
Jan 1, 2024
154.01 M Stocks
Jan 1, 2025
154.01 M Stocks
Jan 1, 2026 (e)
154.01 M Stocks
Jan 1, 2027 (e)
154.01 M Stocks

Imexpharm stock splits

In Imexpharm's history, there have been no stock splits.

Imexpharm Dividend History

18 years of dividend payments

YearAnnual DividendYoY ChangePayments
2025500.00VND↓ 45.0%1×
Jun 9, 2025500.00VND↓ 45.0%1/1
2024909.09VND↓ 4.5%1×
2023952.38VND↓ 36.5%1×
20221,500.00VND 0.0%1×
20211,500.00VND↑ 95.0%1×
2020769.23VND↓ 61.5%1×
20192,000.00VND↑ 63.0%1×
20171,227.27VND↓ 38.6%2×
20162,000.00VND↑ 11.1%1×
20151,800.00VND↑ 20.0%1×

Imexpharm dividend history and estimates

In 2025, Imexpharm paid a dividend amounting to 500.00 VND. Dividend means that Imexpharm distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2020
769.23 VND
0.00 VND
Jan 1, 2021
1,500.00 VND
0.00 VND
Jan 1, 2022
1,500.00 VND
0.00 VND
Jan 1, 2023
952.38 VND
0.00 VND
Jan 1, 2024
909.09 VND
0.00 VND
Jan 1, 2025
500.00 VND
0.00 VND
Jan 1, 2026 (e)
0.00 VND
514.62 VND
Jan 1, 2027 (e)
0.00 VND
529.67 VND

Imexpharm dividend payout ratio

In 2025, Imexpharm had a payout ratio of 25.30%. The payout ratio indicates the percentage of the company's profits that Imexpharm distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
16.39 %
Jan 1, 2021
57.69 %
Jan 1, 2022
54.40 %
Jan 1, 2023
25.20 %
Jan 1, 2024
25.88 %
Jan 1, 2025
25.30 %
Jan 1, 2026 (e)
20.36 %
Jan 1, 2027 (e)
18.08 %

Current Imexpharm forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy83.33 % (5)
Hold16.67 % (1)
Sell0.00 % (0)
12M Price Target
54,570.00
Last Price
39,100.00
Currency
VND
12M Return Potential
39.57 %
LTM Return
0 %

Imexpharm shareholder structure

% Name
47.69714%
SK Investment Vina III Pte. Ltd
SK Investment Vina III Pte. Ltd
22.04351%
Vietnam Pharmaceutical Corporation
Vietnam Pharmaceutical Corporation
9.75708%
Sunrise Kim Investment Joint Stock Company
Sunrise Kim Investment Joint Stock Company
7.37316%
KBA Investment Joint Stock Company
KBA Investment Joint Stock Company
0.52497%
Tran (Dao Thi)
Tran (Dao Thi)
0.44997%
Nguyen (Dinh Quoc)
Nguyen (Dinh Quoc)

Imexpharm Executives and Management Board

CC

Mr. Chaerhan Chun

Chairman of the Board of Management · since 2023

HT

Mr. Hanh Tran

Head of Finance and Accounting Office, Chief Accounting Officer

DT

Ms. Dao Tran

(71)

General Director, Member of the Board of Management · since 2001

NH

Nhung Huynh

(42)

Deputy General Director of Production and Quality Management, Member of the Board of Management · since 2007

PL

Mr. Phuong Le

(43)

Deputy General Director · since 2017

Frequently asked questions about Imexpharm

Analysts currently set an average price target of 54,264.00 VND for the Imexpharm stock (median: 54,570.00 VND), implying +38.8 % versus the latest price. The consensus is based on 6 analyst ratings.

Imexpharm Analyst Price Targets 2026

All fundamentals and in-depth analysis of Imexpharm

Our stock analysis for Imexpharm stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Imexpharm. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Imexpharm Stock
Imexpharm Revenue→
Imexpharm Stock
Imexpharm Net Income→
Imexpharm Stock
Imexpharm P/E→
Imexpharm Stock
Imexpharm P/S→
Imexpharm Stock
Imexpharm EBIT→
Imexpharm Stock
Imexpharm Dividend→
Imexpharm Stock
Imexpharm Directors Dealings→
Imexpharm Stock
Imexpharm Stocks→
Imexpharm Stock
Imexpharm Market capitalization→
Imexpharm Stock
Imexpharm Debt→
Imexpharm Stock
Imexpharm Liabilities→
Imexpharm Stock
Imexpharm Equity→
Imexpharm Stock
Imexpharm AAQS→
Imexpharm Stock
Imexpharm Employees→
Imexpharm Stock
Imexpharm ROE→
Imexpharm Stock
Imexpharm ROA→
Imexpharm Stock
Imexpharm ROCE→
Imexpharm Stock
Imexpharm News→
Imexpharm Stock
Imexpharm Analyst Price Targets→

Health Stocks

ImmaticsImExHSImmix BiopharmaImeik Technology Development CoImmuCellIMD International Medical Devices SpAImmuneeringImaraImmuneOncia TherapeuticsImagion BiosystemsImmuneOnco Biopharmaceuticals ShanghaiImaging Dynamics CoAll Stocks A–Z →